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136 Poster Session IIof the entire group was 47%. The 5 year survival of patients with (n
5 148) or without (n 5 31) CMV/EBV reactivation was respec-
tively: 50%vs 28% (p5 0.02). This was due to a lower risk of relapse
related death (RRD) in patients with reactivation 19% vs 42% (p5
0.005) and similar transplant related mortality (TRM), 28% vs 27%
(p5 0.8). In multivariate analysis disease phase (\5CR2) predicted
survival (RR 0.33) relapse related death (RR 0.50) and TRM (RR
0.72); CMV/EBV reactivation predicted survival (RR 0.69); and
RRD (RR 0.61); RIC transplants were associated with inreased
RRD (RR 4.56).
In conclusion: reactivation of CMV/EBV is a common event in
our transplant prgram. Possibly because of an early diagnosis and
pre-emptive therapy, TRM is comparable in patients with and with-
out infection. Viral reactivation seems to promote the graft versus
leukemia effect of the transplant.371
CO-TRANSPLANTATION OF HUMAN Tregs AND CD341 CELLS: A PRE-
CLINICAL STUDY
Mahmud, D., Chunduri, S., Mahmud, N., Van den Dries, L.,
Maciejewski, J., Rondelli, D. University of Illinois at Chicago, Chicago,
IL.
Co-transplantation of purified CD341 cells and regulatory T
cells (Tregs) might favor the immune reconstitution and limit the
incidence of graft-versus-host disease and graft rejection in an
HLAmismatched transplant setting. In this study we immunomag-
netically selected human CD41CD251 Tregs, which resulted
.80% FoxP3 positive by flow cytometry, and CB CD341 cells.
Then we tested if Tregs would affect CB CD341 cell clonogenic
activity in-vitro an in-vivo, and if co-incubation of Tregs and
CD341 cells may modify the phenotype and function of Tregs. A
colony-forming cells (CFU-C) assay performed with CD341 cells
mixed with allogeneic Tregs at 1:2 ratio resulted in comparable
numbers of Granulocyte- Macrophage CFU (CFU-GM), burst-
forming unit-erythroid (BFU-E) and CFU-Mix as compared to
cultures with CD341 cells alone (p 5 0.2, p 5 0.5 and p 5 0.5,
respectively)(n5 3 exps). Human CD341 cells were then co-trans-
planted with human CD41CD251 allogeneic Tregs into NOD/
SCID mice at 1:1 and 1:2 ratio. After 6 weeks mice marrow was
harvested and showed a 1.3 6 1.1% (n 5 3 mice) and 1.6 6 0.8%
(n 5 4 mice) engraftment of huCD451 cells, respectively, which
was comparable to the engraftment observed in control animals
transplanted with CD341 cells alone (1.4 6 0.4). Among the en-
grafted huCD451 cells similar proportion of CD331 cells,
CD141 monocytes and CD1c1 dendritic cells were observed in
the three groups of animals. Mixed lymphocyte culture (MLC) ex-
periments showed that irradiated CD341 cells stimulated brisk
proliferative responses of allogeneic CD41CD25- cells, but not
of Tregs (n 5 3 exps). After incubation with CD341 cells in the
presence of IL2, on average.80%CD41CD251 cells maintained
the intracellular expression of FoxP3 and surface expression of
CD62L and CD152 (n 5 3 exps). Tregs and CD341 cells were
then isolated from the same CB unit. A primary MLC with irrad
CB CD341 cells and HLA mismatched PB T cell responders was
performed w/wo the addition of CB Tregs at 1:1 ratio with
CD341 cells. A 686 14% (n5 3 exps) inhibition of T cell alloreac-
tivity to CD341 cells was observed in MLC with Tregs. Our find-
ings demonstrate that co-transplantation of CD341 cells andTregs
results in normal stem cell engraftment and potentially reduces
T cell alloreactivity. These results will prompt the design of new
strategies in transplantation of HLA incompatible stem cells by
combining donor-derived CD341 and CD41CD251 cells.372
LEUKEMIC BLASTS ACTING AS HOST ANTIGEN PRESENTING CELLS
TRIGGER A COMBINED CD4 AND CD8 ALLO-IMMUNE RESPONSE DI-
RECTED AGAINST MISMATCHED HLA CLASS I
Amir, A., Hagedoorn, R.S., Marijt, E.A.F., Willemze, R.,
Falkenburg, J.H.F., Heemskerk, M.H.M. Leiden University Medical
Center, Leiden, Netherlands.Single locus HLAmismatched stem cell transplantation (SCT) is
applied in patients with hematological malignancies who may ben-
efit from allogeneic transplantation but lack an HLA-matched do-
nor. Donor lymphocyte infusion (DLI), applied in patients with
mismatched SCT, have a high likelihood of inducing graft versus
host disease (GVHD), however not all patients develop GVHD.
In view of the high frequency of allo-HLA reactive T-cells, and al-
most all nucleated cells express HLA class I, one would expect all
single HLA class I mismatched transplanted patients to develop se-
vere GVHD. We hypothesized therefore that the presentation of
the HLA class I mismatched allele on cells of the patient is not suf-
ficient to elicit an effective allo-immune response.We characterized
the allo-immune response in a patient with acute myeloid leukemia
who was treated with a T-cell depleted SCT from a sibling donor
who was HLA identical except for HLA-A2. Six months after
SCT, DLI was given for mixed chimerism. No clinical response
and no GVHD developed. 12 months after SCT the AML relapsed
with 9% blasts in bone marrow for which a second DLI was given.
Five weeks after the DLI the patient died of grade IVGVHD. Dur-
ing the GVHD conversion to donor chimerism developed. In pe-
ripheral blood of the patient 90% of CD8 and 40% of CD4
donor T-cells were activated as determined by HLA-DR expres-
sion. To analyze the nature of the immune response, the activated
CD8 and CD4 donor T-cells were single cell sorted, expanded
and tested for alloreactivity. Most CD8T-cell clones were alloreac-
tive and restricted to the allo-HLA-A2 molecule. 26% of the CD4
clones were alloreactive, and these clones recognized epitope 103–
120 of the hypervariable region of HLA-A2 in the context of HLA-
DR1. BothT cell responses were highly polyclonal. Prior to the first
DLI, only HLA class I expressing T-cells and non-hematopoietic
patient derived cells were present, these cells were isolated and
were shown to activate the CD8 clones but not the CD4 clones.
Leukemic blasts isolated at the time of the second DLI, expressed
HLA-DR, and activated the CD4 as well as the CD8 clones.We hy-
pothesize that the HLA class II expression on hematopoietic cells of
the patient at the time of the relapse was essential for the develop-
ment of GVHD. These results indicate a role for patient leukemic
blasts acting as host APCs in initiating the GVHD by activating
both a CD4 andCD8T-cell response in anHLA class Imismatched
setting.373
WHAT IS THE ROLE FOR REGULATORY T-CELLS AFTER NONMYELOA-
BLATIVE CONDITIONING?
Humblet-Baron, S., Castermans, E., Vanbellighen, J.-F., Hannon, M.,
Jacobs, N., Beguin, Y., Baron, F. University of Liege, Liege, Belgium.
Purpose:We investigated the association between regulatory T-
cell (T-reg) levels and chronic graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation following
nonmyeloablative conditioning. Methods: Data from 34 patients
given nonmyeloablative conditioning as treatment for hematologi-
cal malignancies were analyzed. Conditioning regimens consisted
of low-doseTBI with or without fludarabine (n5 28), or cyclophos-
phamide plus fludarabine (n 5 6). T-reg (CD41FoxP31) levels on
day 100 were determined by flow cytometry. Chimerism levels
among total white blood cells, CD31 T-cells and
CD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels. Results: Median T-reg fre-
quency (i.e. % of lymphocytes that were CD41FoxP31), T-reg
level and T-reg chimerism on day 100 were 1.7% (0.3–9%), 14
cells/mL (3–127 cells/mL), and 90% (46–100%) respectively. Chi-
merism levels among CD41CD251CD127dim/neg regulatory T-
cells did not correlate with chimerism levels among total white
blood cells (r 5 0.29, P 5 0.31), nor CD31 T-cells (r 5 0.38,
P 5 0.18). Fifteen patients develop chronic GVHD, and 19 did
not. Analyzing data as median, there was not any correlation be-
tween low T-reg frequency, T-reg levels or T-reg chimerism levels
on day 100 and high incidence of chronic GVHD (HR 5 1.7, P 5
0.25; HR 5 1.2, P 5 0.70; and HR 5 0.5, P 5 0.32, respectively).
Finally, T-reg levels correlated weakly with sjTREC levels both as-
sessed on day 100 after transplantation (r 5 0.37, P 5 0.04).
Poster Session II 137Conclusions:Kinetics of T-reg andT-cells engraftment were inde-
pendent, underlying the need for assessing chimerism levels among
each T-cells and T-regs in patients given nonmyeloablative condi-
tioning. Our data did not show any significant correlation between
T-reg levels and occurrence of chronic GVHD thus far. Data in-
cluding higher number of patients will be presented.374
PUVA THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) OF
THE SKIN
Furlong, T., Appelbaum, F.R., Carpenter, P.A., Deeg, J., Doney, K.,
Flowers, M.E.D., Kiem, H.-P., Martin, P.J., Mielcarek, M.,
Nash, R.A., Storb, R. Fred Hutchinson Cancer Research Center, Seattle,
WA.
Glucocorticoids remain the standard for initial treatment of acute
GVHD. However, toxicities and immunosuppression are severe
and steroid-sparing strategies would be desirable. Between 5/96
and 4/07 we treated 55 patients with isolated skin GVHDwith me-
thoxsalen plus ultraviolet-A light therapy (PUVA), with the objec-
tive of avoiding systemic immunosuppressive therapy. Patients
were treated with PUVA three times/week initially at doses of
0.25 J/m2, with exposure increased 0.25 J/m2 per treatment as clin-
ically indicated. The median patient age was 48 (range 4–71) years.
Twenty-six received a calcineurin inhibitor plus mycophenolate
mofetil for GVHD prophylaxis, 24 received a calcineurin inhibitor
plus methotrexate, and 5 received other regimens. Sixteen had re-
lated donors (1 HLA-mismatched), and 39 had unrelated donors
(15 HLA-mismatched). The median onset of GVHD was 26 days
after transplant, and the median start time of PUVA was 43 days.
Forty-five patients received PUVA as initial therapy for acute
GVHD, and 10 patients received PUVA for recurrent GVHD after
discontinuation of prednisone administration. At the start of PUVA
therapy, 31 patients (56%) had rash involving . 50% body surface
area (BSA), 19 (35%) had rash 26–50% BSA and 5 (9%) had rash#
25% BSA. The median number of PUVA treatments was 13 (range
2–26). Sixteen patients (29%) had complete responses after amedian
of 14 (range 8–26) PUVA treatments and required no subsequent
systemic immunosuppressive therapy for treatment of acute
GVHD. Twelve patients required systemic therapy after starting
PUVA for treatment of isolated gastrointestinal GVHD, although
8 of these patients had cleared or improved skin rash before starting
systemic therapy. Twenty-four patients (44%) required systemic
immunosuppressive therapy after starting PUVA for treatment of
skinGVHD (18) or skin plus gastrointestinal GVHD (6). Three pa-
tients had evidence of skin GVHD when PUVA was discontinued
early due to readmission to the hospital or discharge home. Only
four patients required secondary systemic therapy for treatment of
acute GVHD.Thirty-one of 52 patients who could be evaluated de-
veloped chronicGVHD.Thirty-seven patients remain alive at ame-
dian of 753 days after transplant. Overall, 24 of 55 patients (44%)
responded to PUVAwith resolution or improvement of rash. These
results suggest that PUVA can be effective in treating skin GVHD
and in reducing the need for systemic immunosuppressive treat-
ment.375
THE ANALYSIS OF CHRONIC GVHD AFTER CORD BLOOD TRANSPLANTA-
TION IN COMPARISON WITH BONE MARROW TRANSPLANTATION
Seo, S., Uchida, N., Yamamoto, H., Takagi, S., Tsuji, M., Kato, D.,
Matsuno, N., Masuoka, K., Wake, A., Taniguchi, S. Toranomon Hospi-
tal, Tokyo, Japan.
Backgrounds: Umbilical cord blood can be an alternative stem
cell source for the patients with hematological malignancies requir-
ing allogeneic stem cell transplantation. However, little is known
about graft versus leukemia/lymphoma (GVL) effect in cord blood
transplantation (CBT). Here, we analyzed chronic GVHD
(cGVHD) in CBT compared with that in BMT and evaluated the
relevance between cGVHD andGVL.Patients/Methods:We ret-rospectively studied 162 patients who had been free from disease
progression for more than 100 days after either unrelated BMT (n
5 75) or CBT (n 5 87) at Toranomon Hospital from January
2002 to December 2006. Median age of the patients was 52 years
old (BMT vs CBT: 49 vs 53). Underlying diseases were acute leuke-
mia (n 5 88), myelodysplastic syndrome (n 5 17), lymphoma (n 5
39) and others (n 5 18). Conditioning regimens were mainly com-
posed of Fludarabine 125–180 mg/m2 with several combinations of
Melphalan 80–140 mg/m2, Busulfan 8–16 mg/kg and/or total body
irradiation (4–8 Gy).Results:TheMedian observation period after
the transplantationwas 612 days (range, 109–1944). The cumulative
incidence of cGVHD was 84% in BMT and 62% in CBT (p 5
0.09). The severity of cGVHD was analyzed based on its type; lim-
ited or extensive. In CBT, the percentage of the former type was
34% (vs 25% in BMT) and the latter was 23% (vs 48% in BMT).
High-risk disease (p 5 0.03) and preceding acute GVHD(p 5
0.03) are related to the occurrence of cGVHD. RICBT tended to
increase cGVHD compared to CBT using BU/CY or CY/TBI reg-
imen. Multivariative analysis showed that cGVHD increased over-
all survival rate (p\0.01) and suppressed recurrence of the disease
(p\0.01). During observation period, no patients after CBT were
died of cGVHD. Discussion: We demonstrated that cGVHD in
CBT is tolerable compared with that in BMT and that the occur-
rence of cGVHD could result in good prognosis. Our analysis
also suggested that CBT could have GVL effect as well as BMT.376
PERSISTENT RECIPIENT ANTIGEN-PRESENTING CELLS IN HUMAN HE-
MATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF
A DERMAL SUBSET THAT OUTLIVES EPIDERMAL LANGERHANS CELLS
Haniffa, M.1, Ginhoux, F.2, Abel, M.2, Bullock, S.1, Alshemali, S.1,
Merad, M.2, Collin, M.P.1,2. 1Newcastle University, Newcastle upon
Tyne, United Kingdom; 2Mount Sinai School of Medicine, New York.
Graft versus host disease (GVHD), a lethal complication of he-
matopoietic stem cell transplantation (HSCT), is initiated by recip-
ient antigen presenting cells (APC) priming donorT cells. The skin,
a commonly affected organ, contains diverse APC including hetero-
geneous dermal dendritic cells (DC) whose contribution to GVHD
is not well understood.
We have obtained 22 pairs of skin biopsies pre and post condi-
tioning (high dose BuCy or CyTBI and reduced intensity Flu/
Mel) and 85 biopsies at day 40, 100 and 365 post HSCT from pa-
tients with sex-mismatched donors. Pre and post conditioning sam-
ples were digested and analysed with CD45, HLA-DR, CD14 and
CD1a antibodies in a single step Trucount protocol. Chimerism
was determined on cytospins of spontaneously migrated dermal
APC and collagenase digested dermal cells using sequential four-
colour confocal microscopy and X/Y fluorescence in situ hybridiza-
tion.
We find 3 populations of CD451 DR1 dermal cells: CD141
CD1a- fXIIIa-; CD141 CD1a- fXIIIa1; CD1a1 CD14- fXIIIa-.
Characterization of these cells in vitro shows that CD141 cells
are more adherent and phagocytic than CD1a1 cells and that the
fXIIIa1 component is in addition, heavily granulated with ingested
melanin. CD141 APC are resistant to depletion by conditioning
(210 pre/213 post; cells per mm2; P 0.86) compared with CD1a1
cells (201 pre/97 post; mean cells per mm2; P 0.03). Both are re-
duced in HSCT patients compared with controls (706 CD141
and 468 CD1a1 cells per mm2; both P 0.01).
Chimerism analysis at 40, 100 and 365 days post HSCT reveals
two strikingly different patterns of engraftment. CD1a1 and
CD141 fXIIIa- cells, obtained either bymigration or digestion, en-
graft rapidly in all patients, ahead of LC, reaching medians of 99%
and 100% donor, respectively, at day 40. In contrast, CD141
fXIIIa1 cells, which are obtained only from digested dermis, are
very slow to engraft in the absence of GHVD, reaching only 63%
median donor after high dose and 10%median donor chimerism af-
ter reduced regimens, at 1 year. Acute GVHD promotes engraft-
ment with 100% donor chimerism seen in nearly all patients at
day 100. Cell cycle analysis ndicates that these cells are not actively
synthesizing DNA, suggesting a different mode of survival com-
pared with persistent recipient LC.
